If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Revenue from operations climbed 13% to Rs. 886.87 crore
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
